Synchrogenix
Synchrogenix provides strategic regulatory writing and submission services to pharmaceutical and biotechnology sponsors, covering clinical, nonclinical, and CMC documentation, eCTD publishing, and submission leadership for IND, NDA, BLA, and MAA filings globally.
- Company typePrivate
- Founded1986
- HeadquartersWilmington, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
What Synchrogenix does
Synchrogenix is a U.S.-based specialist provider of strategic regulatory writing and related services for the pharmaceutical and biotechnology industry, founded in 1986 and headquartered in Wilmington, Delaware. The company delivers documentation across the full regulatory lifecycle — including clinical, nonclinical, and CMC writing, submission leadership for IND/NDA/BLA/MAA filings, eCTD publishing and validation, clinical disclosure and transparency, aggregate safety reporting, and document quality management. Service delivery is anchored by a writing organization of 200+ regulatory writers, editors, and submission experts with a documented track record of supporting the majority of recent FDA approvals and global submissions across FDA, EMA, and other international agencies. The company expanded via the January 2015 acquisition of ClinGenuity, and operates in close association with Veristat, a full-service clinical research organization, enabling integrated delivery across clinical operations, biostatistics, regulatory affairs, and pharmacovigilance.
Synchrogenix generates revenue through professional services engagements on a quote-based, project- and program-priced model. Go-to-market is enterprise field sales, with direct engagement with pharmaceutical sponsors and biotechnology companies at critical submission milestones (e.g., database lock, NDA/BLA/MAA preparation). Customer segmentation is vertical: pharmaceutical sponsors, biotechnology companies (including cell and gene therapy and vaccine developers), and rare disease/pediatric sponsors. Marketing is delivered through a content library of white papers, factsheets, webinars, podcasts, and case studies, with 'Talk to an expert' and RFP CTAs converting into program-level engagements. The addressable market — global medical writing — is projected to grow from $4.83B in 2024 to $10.67B in 2032 at a 10.4% CAGR, driven by oncology, rare disease, and biologics pipeline expansion, providing a strong secular backdrop.
Synchrogenix firmographics
Firmographics- Name
- Synchrogenix
- Legal name
- Synchrogenix
- Website
- https://synchrogenix.com
- Company type
- Private
- Founded year
- 1986
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Synchrogenix provides strategic regulatory writing and submission services to pharmaceutical and biotechnology sponsors, covering clinical, nonclinical, and CMC documentation, eCTD publishing, and submission leadership for IND, NDA, BLA, and MAA filings globally.
- Ownership category
- akta.pro rank
Synchrogenix industry classification
Industry- Product category
- Regulatory Writing and Submission Services
- NAICS
- Document Preparation Services (56141)
- SIC
- Miscellaneous Publishing (2741)
- akta.pro primary industry
- Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)
- akta.pro secondary industries
- Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH), Regulatory Submissions & Clinical Content Management (eCTD/Publishing) (HLACAOAN)
Keywords
Where Synchrogenix is headquartered
LocationHeadquarters
- HQ city
- Wilmington
- HQ country
- United States
- HQ region
- North America
Markets served
Synchrogenix business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Regulatory Writing Services: Professional services revenue generated through regulatory writing, submissions support, and consulting engagements. Services are provided to pharmaceutical, biotechnology, and life sciences sponsors requiring regulatory documentation for drug approvals.
- Medical Writing Services: Medical writing services supporting clinical research expansion. Revenue driven by increasing clinical trial activity, regulatory complexity, and outsourcing trends in the life sciences sector.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Synchrogenix product offering
Product offeringCore offering
Synchrogenix provides strategic regulatory writing and related services for the pharmaceutical and biotech industry, delivering clear and compliant documentation across clinical, nonclinical, and CMC areas. The company leads submissions for IND, NDA, BLA, and MAA filings, and supports sponsors with clinical disclosure and transparency, eCTD publishing and validation, aggregate safety reporting, and document quality management. Engagements are scope-tied, ranging from targeted expertise to full program ownership at critical submission points.
Differentiator
Problem solved
Functional benefit
Products and services
- Regulatory Writing Services Strategic regulatory writing and related services delivering clear, compliant documentation across clinical, nonclinical, and CMC areas for pharmaceutical and biotechnology sponsors preparing regulatory submissions.
- Medical Writing Services Medical writing services supporting clinical research and regulatory documentation for pharmaceutical, biotechnology, and life sciences sponsors, driven by clinical trial activity, regulatory complexity, and outsourcing trends.
Quantifiable outcome
- Rolling BLA submission delivered ahead of schedule despite shifting timelines
Companies that use Synchrogenix
Customer profileSegments3 records
Ideal customer profiles3 records
Synchrogenix technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Synchrogenix partnerships and signals
Strategic signalScale indicators4 records
Recent moves3 records
Expansion highlights4 records
Synchrogenix competitors and assessment
Company assessmentDirect peers
- Veristat: Mid-size CRO with a regulatory writing practice (IND/NDA/BLA submissions, eCTD publishing) that overlaps directly with Synchrogenix's offerings. Provided source data attributes Synchrogenix's described talent pool and capabilities to Veristat, indicating close operational overlap or a brand/affiliation relationship.
- Worldwide Clinical Trials: Mid-size global CRO with a focused regulatory writing and submissions offering that closely mirrors Synchrogenix's positioning — mid-sized alternative frequently considered by biotech sponsors.
- Premier Research: Specialty CRO with a strong regulatory writing practice particularly in rare disease, oncology, and pediatric programs — competes directly with Synchrogenix in the same therapeutic niches.
- Celerion: Early-phase clinical research organization offering regulatory writing and submission support to small and mid-sized biopharma sponsors — comparable scale and customer profile to Synchrogenix.
- Trilogy Writing & Consulting: Boutique regulatory and medical writing consultancy specializing in clinical study reports, IBs, and submission documents — the closest pure-play specialist comp for Synchrogenix's service offering.
Broad incumbents
- Parexel International: Global full-service CRO offering regulatory writing, medical writing, eCTD publishing, and submission services as part of a broader clinical and biometrics portfolio — directly competes for the same enterprise pharma writing budgets.
- IQVIA: Largest CRO with integrated medical/regulatory writing, regulatory operations, and submission capabilities bundled into enterprise clinical development contracts — a key competitor for sponsor writing budgets.
- ICON plc: Full-service global CRO offering regulatory and medical writing, eCTD submissions, and clinical documentation as part of its clinical research services portfolio — direct overlap for sponsor-level writing engagements.
- Syneos Health: Global clinical and commercial solutions provider with a medical/regulatory writing practice that competes with specialized writing firms, particularly for biotech sponsor programs.
- Medpace: Mid-to-large full-service CRO with in-house regulatory and medical writing capabilities supporting biopharma sponsors from IND through submission — competes for the same regulatory writing scope.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights5 records
Customer concentration
Synchrogenix social profiles
Digital presenceSynchrogenix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Synchrogenix leadership team
Management profileNumber of profiles
Profiles1 record
Synchrogenix funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Synchrogenix M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Synchrogenix
What does Synchrogenix do?
Synchrogenix provides strategic regulatory writing and related services for the pharmaceutical and biotech industry, delivering clear and compliant documentation across clinical, nonclinical, and CMC areas. The company leads submissions for IND, NDA, BLA, and MAA filings, and supports sponsors with clinical disclosure and transparency, eCTD publishing and validation, aggregate safety reporting, and document quality management. Engagements are scope-tied, ranging from targeted expertise to full program ownership at critical submission points.
When was Synchrogenix founded?
Synchrogenix was founded in 1986. It employs 101 to 250 people.
Where is Synchrogenix based?
Synchrogenix is headquartered in Wilmington, United States, in the North America region.
How does Synchrogenix make money?
Two revenue lines are on record. Regulatory Writing Services are the primary driver. The others are medical Writing Services.
Who are Synchrogenix's main competitors?
Direct peers on record are Veristat, Worldwide Clinical Trials, Premier Research, Celerion and Trilogy Writing & Consulting. Broad incumbents are Parexel International, IQVIA, ICON plc, Syneos Health and Medpace.
Does Synchrogenix have an API?
No public API is recorded for Synchrogenix.
What industry is Synchrogenix in?
Synchrogenix's product category is Regulatory Writing and Submission Services. Its primary akta.pro industry code is HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA), with a secondary code of HLAGAAAG, Medical Writing & Regulatory Submission Support CROs. Its NAICS code is 56141 and its SIC code is 2741.